Arecor Therapeutics PLC (GB:AREC) has released an update.
Arecor Therapeutics PLC reports a strong financial year with a 90% growth in revenue and significant progress in its diabetes portfolio. The company’s first Arestat™-enabled product launched commercially, generating royalties, and further partnership expansion. Arecor is poised for key clinical trial outcomes in H1 2024, as it advances its proprietary diabetes treatment candidates.
For further insights into GB:AREC stock, check out TipRanks’ Stock Analysis page.
